Ftse Mib
34.461,00
-1,05%
DAX
18.686,83
-0,43%
S&P 500
5.308,13
0,09%
NASDAQ
16.794,87
0,65%
Bitcoin
70.984,37
-0,65%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Rhythm Pharmaceuticals Inc (RYTM) Rhythm Pharmaceuticals Inc (RYTM) Notizie

RYTM

Rhythm Pharmaceuticals (RYTM)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:RYTM
DataOraFonteTitoloSimboloCompagnia
13/05/202422:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RYTMRhythm Pharmaceuticals Inc
09/05/202422:17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RYTMRhythm Pharmaceuticals Inc
09/05/202422:01GlobeNewswire Inc.Rhythm Pharmaceuticals Announces New Employment Inducement GrantsNASDAQ:RYTMRhythm Pharmaceuticals Inc
07/05/202422:43Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RYTMRhythm Pharmaceuticals Inc
07/05/202413:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RYTMRhythm Pharmaceuticals Inc
07/05/202413:00GlobeNewswire Inc.Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business UpdateNASDAQ:RYTMRhythm Pharmaceuticals Inc
06/05/202414:00GlobeNewswire Inc.Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual MeetingNASDAQ:RYTMRhythm Pharmaceuticals Inc
30/04/202400:30GlobeNewswire Inc.Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & EndocrinologyNASDAQ:RYTMRhythm Pharmaceuticals Inc
24/04/202422:01GlobeNewswire Inc.Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024NASDAQ:RYTMRhythm Pharmaceuticals Inc
01/04/202414:00GlobeNewswire Inc.Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock FinancingNASDAQ:RYTMRhythm Pharmaceuticals Inc
25/03/202413:00GlobeNewswire Inc.Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific AgonistNASDAQ:RYTMRhythm Pharmaceuticals Inc
06/03/202422:01GlobeNewswire Inc.Rhythm Pharmaceuticals Announces Participation at Upcoming Investor ConferencesNASDAQ:RYTMRhythm Pharmaceuticals Inc
29/02/202422:58Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RYTMRhythm Pharmaceuticals Inc
29/02/202422:44Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RYTMRhythm Pharmaceuticals Inc
29/02/202422:05Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RYTMRhythm Pharmaceuticals Inc
22/02/202413:01GlobeNewswire Inc.Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in JapanNASDAQ:RYTMRhythm Pharmaceuticals Inc
22/02/202413:00GlobeNewswire Inc.Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business UpdateNASDAQ:RYTMRhythm Pharmaceuticals Inc
07/02/202414:00GlobeNewswire Inc.Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl SyndromeNASDAQ:RYTMRhythm Pharmaceuticals Inc
31/01/202414:00GlobeNewswire Inc.Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024NASDAQ:RYTMRhythm Pharmaceuticals Inc
04/01/202413:00GlobeNewswire Inc.Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640NASDAQ:RYTMRhythm Pharmaceuticals Inc
04/01/202412:58GlobeNewswire Inc.Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional UpdatesNASDAQ:RYTMRhythm Pharmaceuticals Inc
13/12/202313:00GlobeNewswire Inc.Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023NASDAQ:RYTMRhythm Pharmaceuticals Inc
06/12/202313:00GlobeNewswire Inc.Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D EventNASDAQ:RYTMRhythm Pharmaceuticals Inc
07/11/202313:00GlobeNewswire Inc.Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business UpdateNASDAQ:RYTMRhythm Pharmaceuticals Inc
02/11/202313:00GlobeNewswire Inc.Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)NASDAQ:RYTMRhythm Pharmaceuticals Inc
25/10/202314:00GlobeNewswire Inc.Rhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023NASDAQ:RYTMRhythm Pharmaceuticals Inc
17/10/202322:01GlobeNewswire Inc.Rhythm Pharmaceuticals Presents Data from its Long-term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Year at ObesityWeek® 2023NASDAQ:RYTMRhythm Pharmaceuticals Inc
10/10/202314:00GlobeNewswire Inc.Rhythm Pharmaceuticals Announces Six Abstracts to be Presented at The Obesity Society’s Annual Meeting at ObesityWeek ®NASDAQ:RYTMRhythm Pharmaceuticals Inc
22/09/202314:00GlobeNewswire Inc.Rhythm Pharmaceuticals Presents New Data at ESPE 2023NASDAQ:RYTMRhythm Pharmaceuticals Inc
19/09/202314:01GlobeNewswire Inc.Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic ObesityNASDAQ:RYTMRhythm Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:RYTM

La tua Cronologia

AQSE
XDJP.GB
Deutsche Bank Luxembourg
NYSE
B
Barnes
ASX
EXT
Excite Technology Services
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network